tiprankstipranks
Nuo Therapeutics (AURX)
OTHER OTC:AURX
US Market

Nuo Therapeutics (AURX) Stock Price & Analysis

10 Followers

AURX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.40 - $2.40
Previous Close$0.78
Volume602.00
Average Volume (3M)4.69K
Market Cap
$33.40M
Enterprise Value$33.61M
Total Cash (Recent Filing)$928.68K
Total Debt (Recent Filing)$255.59K
Price to Earnings (P/E)-10.3
Beta-3.18
Aug 08, 2022
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding44,241,516
10 Day Avg. Volume833
30 Day Avg. Volume4,688
Standard Deviation1360.68
R-Squared0.00105
Alpha195.65
Financial Highlights & Ratios
Price to Book (P/B)34.06
Price to Sales (P/S)179.65
Price to Cash Flow (P/CF)-13.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue55.24
Enterprise Value/Gross Profit45.76
Enterprise Value/Ebitda-10.96
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

77.37%0.00%0.00%22.63%
77.37% Insiders
0.00% Other Institutional Investors
22.63% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

AURX FAQ

What was Nuo Therapeutics’s price range in the past 12 months?
Nuo Therapeutics lowest stock price was $0.40 and its highest was $2.40 in the past 12 months.
    What is Nuo Therapeutics’s market cap?
    Currently, no data Available
    When is Nuo Therapeutics’s upcoming earnings report date?
    Nuo Therapeutics’s upcoming earnings report date is Aug 08, 2022 which is 637 days ago.
      How were Nuo Therapeutics’s earnings last quarter?
      Currently, no data Available
      Is Nuo Therapeutics overvalued?
      According to Wall Street analysts Nuo Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Nuo Therapeutics pay dividends?
        Nuo Therapeutics does not currently pay dividends.
        What is Nuo Therapeutics’s EPS estimate?
        Nuo Therapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Nuo Therapeutics have?
        Nuo Therapeutics has 44,241,516 shares outstanding.
          What happened to Nuo Therapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Nuo Therapeutics?
          Currently, no hedge funds are holding shares in AURX
          ---

          Nuo Therapeutics Stock Smart Score

          N/A
          Not Ranked
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Positive
          20 days / 200 days
          Momentum
          -65.55%
          12-Months-Change

          Fundamentals

          Return on Equity
          -196.34%
          Trailing 12-Months
          Asset Growth
          -38.38%
          Trailing 12-Months

          Company Description

          Nuo Therapeutics

          Nuo Therapeutics, Inc. engages in developing and marketing products for chronic wound care. It offers Aurix point of care technology for the safe and efficient separation of autologous blood to produce a platelet based therapy for the chronic wound care market. The company was founded on April 29, 1998 and is headquartered in Gaithersburg, MD.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          BioCryst
          Brainstorm Cell Therapeutics
          Cytokinetics
          Geron
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis